Literature DB >> 6510876

Haemodynamic dose-response effects of i.v. verapamil in coronary artery disease.

B Silke, S P Verma, R C Ahuja, G I Nelson, M Hussain, S H Taylor.   

Abstract

As an aid to clinical therapeutic decisions, the haemodynamic dose-response effects following intravenous verapamil were evaluated in ten male patients with angiographically confirmed and stable coronary artery disease. Sitting at rest, following a control period with four i.v. boluses of saline, four equivalent boluses of verapamil (logarithmic cumulative dosage; 2, 4, 8 and 16 mg) were administered at four minute intervals; haemodynamic variables were recorded two to four minutes following each i.v. injection. The haemodynamic effects of the drug during upright bicycle exercise were evaluated by comparison of measurements made during a control steady-state exercise period with observations made at the same upright exercise workload (25 to 75 W) immediately following the maximum cumulative dose (16 mg). Following the four i.v. boluses, the plasma verapamil concentrations showed a log-linear increase (r = 0.82; p less than 0.001); the levels achieved (26 +/- 2 to 147 +/- 14 micrograms/l) were within the range at which substantial pharmacodynamic activity has been shown to be present. At rest, compared with control measurements after saline, these plasma concentrations of verapamil were associated with linear decreases in systemic vascular resistance (maximum delta SVR -720 dyne X s X cm-5/m2; p less than 0.01) and blood pressure (maximum delta MBP -8 mmHg; p less than 0.05) and linear increases in cardiac index (maximum delta CI +0.4 l/min/m2; p less than 0.05) and in pulmonary artery occluded pressure (maximum delta PAOP +3 mmHg; p less than 0.05). There was no significant trend of change in the heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6510876

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  4 in total

1.  A haemodynamic and radionuclide assessment of diltiazem in coronary heart disease.

Authors:  B Silke; S K Sharma; S P Verma; K A Midtbo; G Reynolds; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

2.  Haemodynamic and radionuclide effects of amlodipine in coronary artery disease.

Authors:  B Silke; S P Verma; A V Zezulka; S Sharma; G Reynolds; N C Jackson; S Guy; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

3.  An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease.

Authors:  B Silke; E Goldhammer; S K Sharma; S P Verma; S H Taylor
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

4.  Haemodynamic dose-response effects of intravenous nisoldipine in coronary artery disease.

Authors:  B Silke; M A Frais; P Muller; S P Verma; G Reynolds; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.